Drugs / E39 peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01580696 | Apr 2012 → Jul 2016 | endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneum cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E39 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01580696 ↗ |
| Known as | E39 peptide (FBP, 191-199, EIWTHSTKV) | “E39 peptide (FBP, 191-199, EIWTHSTKV)” NCT01580696 ↗ |
| Modality | Peptide | “peptide-based vaccine consisting of the E39 peptide mixed with the FDA-approved immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF)” NCT01580696 ↗ |